Apimeds Pharmaceuticals US I
13F holders, Q3 2025 (September 30)8holders +2
6new positions
4sold out
1famous investor
$1.78avg. 13F price*
At the end of Q3 2025, 8 institutions reported holding Apimeds Pharmaceuticals US I in their 13F filings, up 2 from Q2 2025. 6 opened new positions and 4 sold out. The largest holders were Hemenway Trust Co LLC ($445K), Vanguard Group Inc. ($105K) and Geode Capital Management, LLC ($55K). One famous investor held it Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Apimeds Pharmaceuticals US I
- CUSIP
- 03771D102
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $712K |
| Exits | 4 | $490K |
All 13F filers, Q2 2025 → Q3 2025: 399,949 shares bought and 278,497 shares sold, net +121,452 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Hemenway Trust Co LLC | 0.03% | New | 250,000 | $445K |
| Vanguard Group Inc. | 0.00% | New | 58,992 | $105K |
| Geode Capital Management, LLC | 0.00% | New | 30,754 | $55K |
| Renaissance Technologies | 0.00% | New | 27,893 | $50K |
| XTX Topco Ltd | 0.00% | New | 18,735 | $33K |
| HRT Financial LP | 0.00% | New | 13,572 | $24K |
| Bank of America Corp. | 0.00% | No change | 29 | $52 |
| JPMorgan Chase & Co. | 0.00% | Add +60.0% | 8 | $14 |
"% of holder's portfolio" is APIMEDS PHARMACEUTICALS US I's weight in each manager's 13F, not the share of Apimeds Pharmaceuticals US I the manager owns.